GlassScriptPhysician profile
Jay C Guido
NPI 1164479598
$4,820.07
in general payments reported to CMS, 2019-2025
30 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $279 · 2021: $520 · 2022: $572 · 2023: $709 · 2024: $555 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,514.21 | 2019-2020 | |
| Astellas Pharma US INC | $544.73 | 2019-2024 | Myrbetriq |
| Sumitomo Pharma America, INC. | $524.87 | 2023-2025 | Orgovyx, Gemtesa |
| Myriad Genetic Laboratories, INC. | $247.41 | 2023-2025 | Prolaris |
| Teleflex LLC | $246.77 | 2022-2025 | Urolift, Barrigel |
| Axonics, INC. | $209.23 | 2020-2023 | Axonics |
| Pfizer INC. | $157.98 | 2019-2023 | |
| Boston Scientific Corporation | $144.46 | 2019-2024 | Spaceoar Vue System - 10ml |
| Abbvie INC. | $130.16 | 2023-2025 | |
| Allergan, INC. | $125.51 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $111.14 | 2019-2021 | |
| Antares Pharma, INC. | $108.44 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Myovant Sciences INC. | $108.08 | 2021-2022 | |
| Urovant Sciences INC | $87.24 | 2022 | |
| Tolmar, INC. | $77.00 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $70.71 | 2019-2020 | |
| Coloplast Corp | $47.72 | 2020-2021 | |
| Clarus Therapeutics INC. | $43.63 | 2021 | |
| 180 Medical, INC. | $34.16 | 2019 | |
| Blue Earth Diagnostics | $33.15 | 2019-2021 | |
| Olympus America INC. | $32.88 | 2024-2025 | Itind System |
| Ferring Pharmaceuticals INC. | $32.77 | 2024 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $31.85 | 2025 | Provenge |
| Verity Pharmaceuticals INC. | $30.64 | 2024 | Trelstar |
| Procept Biorobotics Corporation | $30.48 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $23.12 | 2022 | |
| Halozyme INC | $22.81 | 2023 | |
| Aytu Biopharma, INC. | $22.28 | 2019 | |
| Smith+Nephew, INC. | $19.17 | 2024 | Grafix Pl |
| Civco Medical Instruments | $7.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Guido listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.